Driving CAR T Cells against Solid Tumors.
Journal
Cancer discovery
ISSN: 2159-8290
Titre abrégé: Cancer Discov
Pays: United States
ID NLM: 101561693
Informations de publication
Date de publication:
06 07 2022
06 07 2022
Historique:
pubmed:
30
4
2022
medline:
8
7
2022
entrez:
29
4
2022
Statut:
ppublish
Résumé
During the American Association for Cancer Research Annual Meeting 2022, researchers discussed ways to improve chimeric antigen receptor T-cell therapy's efficacy in solid tumors. These included sussing out differences between solid and blood cancers in their susceptibility to CAR T cells' cytotoxicity, taking a modular approach to engineering next-generation agents, and building in breaks for exhaustion-prone CAR T cells to restore their function.
Identifiants
pubmed: 35485880
pii: 694819
doi: 10.1158/2159-8290.CD-ND2022-0006
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
OF4Informations de copyright
©2022 American Association for Cancer Research.